The cytomegalovirus (CMV) infection therapeutic market comprises treatments used for managing cytomegalovirus infections. CMV is a type of herpes virus that causes disease in people with a weakened immune system. Some of the commonly used therapeutics include ganciclovir, valganciclovir, and foscarnet. These drugs help reduce the replication of the virus
by inhibiting viral DNA polymerase.
The global CMV infection therapeutic market is estimated to be valued at US$ 231.4 Mn in 2024 and is expected to exhibit a CAGR of 7.1% over the forecast period 2024-2031.
Key players operating in the CMV infection therapeutic market include Moderna, Trellis Bioscience, SpyBiotech, Vical, and Atara Biotherapeutics. Moderna is developing an mRNA-based CMV vaccine candidate (mRNA-1647) to prevent primary CMV infection and disease in healthy individuals. Trellis Bioscience is developing TRL-003, an adoptive T-cell therapy targeting CMV. SpyBiotech is developing a therapeutic vaccine candidate called CMV-Trimer for the prevention and treatment of CMV infection.
The growing geriatric population and rising number of organ transplant procedures are driving the demand for CMV infection therapeutics. As per estimates, over 50% of adults aged 40-60 years have been exposed to CMV. Furthermore, the risk of CMV infection is high in immunosuppressed patients. This has created an urgent need for safe and effective treatment options.
The market is also witnessing increased strategic collaborations and regional expansions by key players. For instance, Vical entered into strategic alliances with AnGes and Roche to develop and commercialize its investigational CMV therapeutics outside the United States. Moderna has expanded its global footprint by establishing new manufacturing facilities in Africa, Asia, and Europe. Such initiatives are expected to bolster the global presence of CMV infection treatment over the forecast period.
The rising R&D investments into novel drug formulations is a key trend in the CMV infection therapeutic market. Companies are exploring modalities like mRNA vaccines, adoptive T-cell therapies, and therapeutic vaccines to develop CMV therapies with better safety, efficacy and delivery profiles. Such innovations are anticipated to transform the CMV infection treatment landscape over the coming years.
Porter’s Analysis
Threat of new entrants: High investment and R&D costs to develop new drugs makes the threat of entry low.
Bargaining power of buyers: Large pharmaceutical companies have more bargaining power over pricing.
Bargaining power of suppliers: Dependence on few suppliers for raw materials increases their bargaining power.
Threat of new substitutes: New drug delivery methods and therapeutics pose a threat of substitution.
Competitive rivalry: Intense competition between major manufacturers to launch new drugs drives consolidation in the industry.
North America currently accounts for the largest share of the global CMV infection therapeutics market, primarily due to the large patient pool, increasing healthcare spending, and rising prevalence of CMV infection in the region. The region has high adoption rate of advanced diagnostic tests and therapeutics. Majority of the key pharmaceutical companies are also based in North America, which increases accessibility to therapeutics. Asia Pacific region is expected to witness fastest CAGR during the forecast period owing to growing awareness, increasing healthcare spending, and expansion of key pharmaceutical manufacturers in countries such as China, India and Japan. The large pool of generic manufacturers and rising disposable income contributes to market growth in the region.
Geographical Regions
North America currently accounts for the largest share of the global CMV infection therapeutics market, primarily due to the large patient pool, increasing healthcare spending, and rising prevalence of CMV infection in the region. The region has high adoption rate of advanced diagnostic tests and therapeutics. Majority of the key pharmaceutical companies are also based in North America, which increases accessibility to therapeutics.
Asia Pacific region is expected to witness fastest CAGR during the forecast period owing to growing awareness, increasing healthcare spending, and expansion of key pharmaceutical manufacturers in countries such as China, India and Japan. The large pool of generic manufacturers and rising disposable income contributes to market growth in the region.
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it